STOCK TITAN

Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Scenic Biotech has partnered with Bristol Myers Squibb to utilize its Cell-Seq technology platform in accelerating drug target development. The collaboration involves an upfront payment and potential additional payments tied to research, development, and commercial milestones. This marks Scenic Biotech's second strategic collaboration with a major industry player, showcasing the value of its groundbreaking approach in supporting the creation of innovative medicines.

Scenic Biotech ha stretto una partnership con Bristol Myers Squibb per impiegare la sua piattaforma tecnologica Cell-Seq nell'accelerare lo sviluppo di nuovi bersagli farmacologici. La collaborazione prevede un pagamento iniziale e potenziali ulteriori pagamenti legati a traguardi di ricerca, sviluppo e commercializzazione. Questo rappresenta la seconda collaborazione strategica di Scenic Biotech con un importante attore del settore, dimostrando il valore del suo approccio innovativo nel supporto alla creazione di medicine innovative.
Scenic Biotech se ha asociado con Bristol Myers Squibb para utilizar su plataforma tecnológica Cell-Seq con el fin de acelerar el desarrollo de objetivos farmacológicos. La colaboración incluye un pago inicial y pagos adicionales potenciales vinculados a hitos de investigación, desarrollo y comerciales. Esto marca la segunda colaboración estratégica de Scenic Biotech con un jugador importante de la industria, destacando el valor de su enfoque pionero en el apoyo a la creación de medicamentos innovadores.
Scenic Biotech은 자사의 Cell-Seq 기술 플랫폼을 활용하여 약물 타겟 개발을 가속화하기 위해 Bristol Myers Squibb과 파트너 관계를 맺었습니다. 이 협력은 선불금과 연구, 개발, 상업 단계의 이정표에 따른 추가 지불 가능성을 포함합니다. 이는 주요 업계 플레이어와의 두 번째 전략적 협력을 표시하며, 혁신적인 의약품 창출을 지원하는 그들의 혁신적 접근 방식의 가치를 보여줍니다.
Scenic Biotech s'est associée à Bristol Myers Squibb pour utiliser sa plateforme technologique Cell-Seq dans le but d'accélérer le développement de cibles médicamenteuses. La collaboration comprend un paiement initial et des paiements supplémentaires potentiels liés à des jalons de recherche, de développement et commerciaux. Cela représente la deuxième collaboration stratégique de Scenic Biotech avec un acteur majeur du secteur, soulignant la valeur de son approche novatrice dans le soutien à la création de médicaments innovants.
Scenic Biotech hat sich mit Bristol Myers Squibb zusammengetan, um seine Cell-Seq-Technologieplattform zur Beschleunigung der Entwicklung von Arzneimittelzielen zu nutzen. Die Zusammenarbeit beinhaltet eine Anfangszahlung und potenzielle zusätzliche Zahlungen, die an Forschungs-, Entwicklungs- und kommerzielle Meilensteine geknüpft sind. Dies markiert die zweite strategische Zusammenarbeit von Scenic Biotech mit einem wichtigen Akteur der Branche, was den Wert ihres bahnbrechenden Ansatzes bei der Unterstützung der Schaffung innovativer Medikamente unterstreicht.
Positive
  • Partnership with Bristol Myers Squibb validates Scenic Biotech's Cell-Seq platform's unique capability in linking cellular pathways to drug targets

  • The agreement includes upfront payment and potential additional payments tied to research, development, and commercial milestones, showcasing the growth potential for Scenic Biotech

  • This collaboration demonstrates Scenic Biotech's commitment to advancing disease-modifying therapies and supporting the creation of innovative medicines for severe genetic disorders

Negative
  • No specific financial details about the agreement have been disclosed, leaving investors uncertain about the potential financial impact on Scenic Biotech's revenue

  • The success of the collaboration and the achievement of milestones are essential for Scenic Biotech to receive additional payments, posing a risk if targets are not met

Bristol Myers Squibb gains access to Scenic’s Cell-Seq technology platform to unlock the underlying genetic interactions of cellular pathways for undisclosed targets

Scenic to receive an upfront payment and potential additional payments contingent on the achievement of research, development and commercial milestones

AMSTERDAM--(BUSINESS WIRE)-- Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb (NYSE: BMY) to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion. Under the terms of the agreement, Scenic Biotech will be entitled to an upfront payment and potential additional payments contingent upon achievement of a range of research, development and commercial milestones. No further financial details have been disclosed.

“Working with a world leader in drug discovery and development is an important validation of our Cell-Seq platform’s unique capability to link cellular pathways to drug targets,” commented Oscar Izeboud, PhD, CEO of Scenic Biotech. “As we continue to advance our own pipeline of first-in-class disease-modifying therapies, we remain committed to harnessing the power of our ground-breaking approach to support our collaborators in crafting innovative medicines for patients with devastating conditions.”

The collaboration with Bristol Myers Squibb marks Scenic Biotech’s second strategic collaboration with a major industry partner, following the multi-year genetic modifier collaborative agreement with Genentech announced in 2020. Both collaborations leverage the Cell-Seq platform’s ability to provide genetic insights leading to the discovery and development of novel therapeutics. While Scenic primarily focuses on applying its Cell-Seq technology to identify modifier genes, the technology has demonstrated its ability to map previously unexplored biological pathways and investigate disease biology.

About Scenic Biotech

Scenic Biotech is advancing modifier therapy, a radically new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by acting on another function in the genome that can neutralize the disease impact, leading to a therapeutic effect. Our robust pipeline, derived from our proprietary Cell-Seq platform, includes first-in-class small molecule programs that are either wholly owned or partnered through strategic collaborations with multinational pharmaceutical leaders. By unlocking new pathways in the genome, Scenic will develop a range of modifier therapies to help patients.

Scenic Biotech

Oscar Izeboud, PhD, CEO

Phone: +31 20 7059 990

Email: info@scenicbiotech.com

Trophic Communications

Desmond James & Priscillia Perrin, PhD

Phone: +49 151 6785 9086

Email: scenic@trophic.eu

Source: Scenic Biotech

FAQ

What collaboration has Scenic Biotech entered into with Bristol Myers Squibb?

Scenic Biotech has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of drug targets using its Cell-Seq technology platform.

What payment structure is involved in the collaboration between Scenic Biotech and Bristol Myers Squibb?

The agreement includes an upfront payment and potential additional payments based on the achievement of research, development, and commercial milestones.

What is the significance of this collaboration for Scenic Biotech?

The collaboration with Bristol Myers Squibb validates the value of Scenic Biotech's Cell-Seq platform and demonstrates its commitment to advancing disease-modifying therapies.

Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

BMY Latest News

BMY Stock Data

114.19B
2.03B
0.12%
78.46%
1.27%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
PRINCETON